After consistently delivering on commitments in first two years as standalone company, Sandoz has unique leading position in biosimilar and generic market Strong momentum supports plans to capture ...
Integral Metals Corp. (CSE: INTG | OTC: ITGLF | FSE: ZK9) (the “Company” or “Integral”) is pleased to provide a year-in-review summary ...
U.S. commercial launch in thalassemia underway following December 2025 FDA approvalPre-sNDA meeting with FDA for mitapivat in sickle cell disease anticipated in first quarter of 2026, with planned U.S ...
Positive Phase 3 HERIZON-GEA-01 results for Ziihera (zanidatamab-hrii) in first-line HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA) presented at ASCO GI Up to $440.0 million in milestone ...
Positive Phase 3 HERIZON-GEA-01 results for Ziihera® (zanidatamab-hrii) in first-line HER2-positive (HER2+) gastroesophageal ...
Amazon’s latest move shows how performance management in big tech is evolving, with accountability and evidence now taking ...
XLE Vs. VDE comparison: slight preference for XLE due to lower fees, and catalysts like Venezuela optionality. Read here for ...
The new portfolio acquisition executives will oversee vital Air Force programs, such as advanced planes and nuclear command ...
RedChip Companies will air interviews with Alliance Entertainment Holding Corp. (Nasdaq:AENT) and Processa Pharmaceuticals, Inc. (Nasdaq:PCSA) on the RedChip Small Stocks, Big Money™ show, a sponsored ...
The letter frames EMERGE’s history in three phases, according to the company, and is intended to provide shareholders with a ...
Fury closed an C$18.0 million brokered flow-through financing to advance exploration and development work at Committee Bay and Eau Claire in 2025/2026, strengthening the Company’s balance sheet. The ...
Drew Clark, President and CEO of Summit Royalties Ltd. (TSXV: SUM), outlines why the royalty model continues to outperform ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback